Glial Cell Line Derived Neurotrophic Factor Market By Type ( TW-002, AMT-090, GSK-812, LAUR-301 ), By Application ( Brain Ischemia, Retinal Degeneration, Parkinson's Disease, Amyotrophic Lateral Sclerosis ), Industry Trends, Estimation & Forecast, 2017 - 2025

Check Today's Best Price

$3500 Buy Now
Glial Cell Line Derived Neurotrophic Factor Market is expected to grow with a CAGR of XX% during the forecast period of 2018 to 2025.
  • Market Overview:

    Glial cell-derived neurotrophic factor (GDNF) is a small protein that facilitates the survival of various neurons. It is found to be effective in preventing the apoptosis of motor neurons that is induced by axotomy. The advent of glial cell-derived neurotrophic factor was based on its capability to promote the survival of dopaminergic neurons. However, advancements in technology have linked the importance of GDNF in the treatment of Parkinson’s disease, along with stroke and motoneuron injuries, owing to its ability to regenerate brain cells. According to the Parkinson Association of the Carolinas, every year approximately 60,000 people in America are diagnosed with Parkinson’s disease.

    In addition, globally around 7 to 10 million people are subjected to Parkinson’s disease. Even though the treatment of Parkinson’s disease via GDNF is still under trials, it has shown to be effective in the small clinical trials that have been conducted so far. The major limitation witnessed during the treatment is the administration of GDNF in the form of tablet or injection. Continuous developments and investments in the research studies are expected to drive the growth of global glial cell line derived neurotrophic factor (GDNF) market.

    The report provides detailed qualitative and quantitative analysis of the global glial cell line derived neurotrophic factor market. Market size and forecast in terms of value and volume has been provided for the period – (2017 – 2025), for the segments namely type, and application in each of the major regions of the world.

    Glial Cell Line Derived Neurotrophic Factor Market Segmentation

    By Type
    • TW-002
    • AMT-090
    • GSK-812
    • LAUR-301
    • Others

    By Application
    • Brain Ischemia
    • Retinal Degeneration
    • Parkinson’s Disease
    • Amyotrophic Lateral Sclerosis
    • Others

    By Geography

    North America
    o U.S.
    o Canada
    o Mexico

    Europe
    o U.K
    o France
    o Germany
    o Italy
    o Spain
    o Rest of Europe

    • Asia-Pacific
    o China
    o Japan
    o India
    o Korea
    o Rest of APAC

    • South America
    o Brazil
    o Rest of South America

    • Rest of the World
    o Middle East
    o Africa

    keyboard_arrow_up
  • CHAPTER 1. INTRODUCTION
    1.1. RESEARCH METHODOLOGY
    1.1.1. ERC desk research
    1.1.2. ERC data synthesis
    1.1.3. Data validation and market feedback
    1.1.4. ERC data sources

    CHAPTER 2. GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET OVERVIEW
    2.1. GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET INTRODUCTION
    2.2. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET PRODUCTION AND GROWTH RATE, 2017-2025
    2.2.1. Global Glial Cell Line Derived Neurotrophic Factor Production (VOLUME) and Growth Rate (%), (2017-2025)
    2.3. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET CAPACITY AND GROWTH RATE, 2017-2025
    2.3.1. Global Glial Cell Line Derived Neurotrophic Factor Capacity (VOLUME) and Growth Rate (%), (2017-2025)
    2.4. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET REVENUE AND GROWTH RATE, 2017-2025
    2.4.1. Global Glial Cell Line Derived Neurotrophic Factor Market Revenue (Million USD) and Growth Rate (%), (2017-2025)
    2.5. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
    2.5.1. Global Glial Cell Line Derived Neurotrophic Factor Consumption (VOLUME) and Growth Rate (%), (2017-2025)
    2.6. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET PRICE TREND, 2017-2025
    2.6.1. Global Glial Cell Line Derived Neurotrophic Factor Market Price Trend and Growth Rate (%), (2017-2025)

    CHAPTER 3. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET BY TYPE, 2017-2025
    3.1. AMT-090
    3.2. TW-002
    3.3. GSK-812
    3.4. LAUR-301
    3.5. OTHERS
    3.6. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET REVENUE BY TYPE, 2017-2025
    3.6.1. Global Glial Cell Line Derived Neurotrophic Factor Market Revenue (Million USD) and Share (%) By Type, 2017-2025
    3.6.2. AMT-090 Market Revenue and Growth Rate, 2017-2025
    3.6.3. TW-002 Market Revenue and Growth Rate, 2017-2025
    3.6.4. GSK-812 Market Revenue and Growth Rate, 2017-2025

    Note: Similar information coverage has been provided for other type segment.

    3.7. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET PRODUCTION BY TYPE, 2017-2025
    3.7.1. Global Glial Cell Line Derived Neurotrophic Factor Market Production (Volume) and Share (%) By Type, 2017-2025
    3.7.2. AMT-090 Market Production and Growth Rate, 2017-2025
    3.7.3. TW-002 Market Production and Growth Rate, 2017-2025
    3.7.4. GSK-812 Market Production and Growth Rate, 2017-2025

    Note: Similar information coverage has been provided for other type segment.

    CHAPTER 4. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET BY APPLICATION, 2017-2025
    4.1. BRAIN ISCHEMIA
    4.2. RETINAL DEGENERATION
    4.3. PARKINSON’S DISEASE
    4.4. RETINAL DEGENERATION
    4.5. PARKINSON’S DISEASE
    4.6. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET REVENUE BY APPLICATION, 2017-2025
    4.6.1. Global Glial Cell Line Derived Neurotrophic Factor Market Revenue (Million USD) and Share (%) By Application, 2017-2025
    4.6.2. Brain Ischemia Market Revenue and Growth Rate, 2017-2025
    4.6.3. Retinal Degeneration Market Revenue and Growth Rate, 2017-2025
    4.6.4. Parkinson’s Disease Market Revenue and Growth Rate, 2017-2025
    4.7. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET CONSUMPTION BY APPLICATION, 2017-2025
    4.7.1. Global Glial Cell Line Derived Neurotrophic Factor Market Consumption (Volume) and share (%) By Application, 2017-2025
    4.7.2. Brain Ischemia Market Consumption and Growth Rate, 2017-2025
    4.7.3. Retinal Degeneration Market Consumption and Growth Rate, 2017-2025
    4.7.4. Parkinson’s Disease Market Consumption and Growth Rate, 2017-2025

    Note: Similar information coverage has been provided for other application segment.

    CHAPTER 5. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET BY REGION, 2017-2025
    5.1. NORTH AMERICA
    5.1.1. U.S.
    5.1.2. Canada
    5.1.3. Mexico
    5.2. EUROPE
    5.2.1. U.K.
    5.2.2. France
    5.2.3. Germany
    5.2.4. Italy
    5.2.5. Spain
    5.2.6. Rest of Europe
    5.3. ASIA PACIFIC
    5.3.1. China
    5.3.2. Japan
    5.3.3. India
    5.3.4. Korea
    5.3.5. Rest of APAC
    5.4. SOUTH AMERICA
    5.4.1. Brazil
    5.4.2. Rest of South America
    5.5. REST OF THE WORLD
    5.5.1. Middle East
    5.5.2. Africa
    5.6. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET REVENUE BY REGION, 2017-2025
    5.6.1. Global Glial Cell Line Derived Neurotrophic Factor Market Revenue (Million USD) and Share (%) By Region, 2017-2025
    5.6.2. North America Market Revenue and Growth Rate, 2017-2025
    5.6.3. Europe Market Revenue and Growth Rate, 2017-2025
    5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025
    5.6.5. South America Market Revenue and Growth Rate, 2017-2025
    5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025

    CHAPTER 6. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025
    6.1. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025
    6.1.1. Global Glial Cell Line Derived Neurotrophic Factor Market Production (Volume) and Share (%) By Region, 2017-2025
    6.1.2. Global Glial Cell Line Derived Neurotrophic Factor Market Consumption (Volume) and Share (%) By Region, 2017-2025
    6.1.3. North America Market Production and Consumption, 2017-2025
    6.1.4. Europe Market Production and Consumption, 2017-2025
    6.1.5. Asia Pacific Market Production and Consumption, 2017-2025
    6.1.6. South America Market Production and Consumption, 2017-2025
    6.1.7. Rest of the World Market Production and Consumption, 2017-2025

    CHAPTER 7. MARKET DETERMINANTS
    7.1. MARKET DRIVERS
    7.2. MARKET RESTRAINTS
    7.3. MARKET OPPORTUNITIES
    7.4. MARKET DETERMINANTS RADAR CHART

    CHAPTER 8. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET COMPETITION BY MANUFACTURERS
    8.1. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
    8.1.1. Global Glial Cell Line Derived Neurotrophic Factor Production (VOLUME) and Share (%) by Manufacturers (2017-2025)
    8.2. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
    8.2.1. Global Glial Cell Line Derived Neurotrophic Factor Revenue (Million USD) and Share (%) by Manufacturers (2017-2025)
    8.3. GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET COMPETITIVE SITUATION AND TRENDS
    8.3.1. Glial Cell Line Derived Neurotrophic Factor Market Share (%) of Top 3 Manufacturers
    8.3.2. Glial Cell Line Derived Neurotrophic Factor Market Share (%) of Top 5 Manufacturers

    CHAPTER 9. GLOBAL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MANUFACTURERS ANALYSIS
    9.1. TREEWAY BV
    9.1.1. Business Overview
    9.1.2. Company Basic Information
    9.1.3. Glial Cell Line Derived Neurotrophic Factor Product Details
    9.1.4. Treeway BV Glial Cell Line Derived Neurotrophic Factor Production, Revenue and Gross Margin
    9.2. UNIQURE NV
    9.2.1. Business Overview
    9.2.2. Company Basic Information
    9.2.3. Glial Cell Line Derived Neurotrophic Factor Product Details
    9.2.4. UniQure NV Glial Cell Line Derived Neurotrophic Factor Production, Revenue and Gross Margin
    9.3. GLAXOSMITHKLINE PLC
    9.3.1. Business Overview
    9.3.2. Company Basic Information
    9.3.3. Glial Cell Line Derived Neurotrophic Factor Product Details
    9.3.4. GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Production, Revenue and Gross Margin

    CHAPTER 10. GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR MARKET VALUE CHAIN ANALYSIS
    10.1. GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR INDUSTRIAL CHAIN ANALYSIS
    10.2. GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR KEY RAW MATERIALS ANALYSIS
    10.2.1. Key Raw Materials
    10.2.2. Price Trend of Key Raw Materials
    10.2.3. Key Suppliers of Raw Materials
    10.3. MARKETING CHANNEL
    10.3.1. Direct Marketing
    10.3.2. Indirect Marketing
    10.3.3. Distributors/Traders
    10.4. CONSUMER ANALYSIS
    10.4.1. Consumer 1
    10.4.2. Consumer 2
    10.4.3. Consumer 3
    10.4.4. Consumer 4

    keyboard_arrow_up
  • • Treeway BV
    • UniQure NV
    • GlaxoSmithKline Plc

    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

What Information does this report contain?

• What was the market size of the Glial Cell Line Derived Neurotrophic Factor Market in 2017 and the expected market size by 2025, along with the growth rate?
• An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
• Which are the largest revenue generating products, services or regions and their comparative growth rate?
• Which technology is in trend and how would it evolve during the forecast period (2017 – 2025)?
• Which are the leading companies in the Glial Cell Line Derived Neurotrophic Factor Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

CLIENTS